ERBB2 and non-small cell lung carcinoma: Although a multicenter, randomized phase III trial (NCT04447118) has been started to verify the efficacy and safety of pyrotinib versus docetaxel in patients with previously treated, advanced non-squamous NSCLC harboring HER2 exon 20 mutations, we considered that a combination regimen is worth of exploration to further enhance the antitumor activity and improve the safety and tolerability of pyrotinib.